

Index*

A

- Abscesses, 171
- Acceptable Macronutrient Distribution
Range (AMDR), 3
- Achlorhydria, 37
- Acronyms and abbreviations, 523–526
- Adequate Intake (AI), 3, 8, 20, 21–22,
489–490. *See also* Calcium, AIs;
Vitamin D, AIs
- Adipokines, 491
- Adipose tissue, 83, 84, 87–88, 106, 490, 491,
518
- Adiposity, 11, 84, 105–106, 143, 152, 156,
490–491. *See also* Obese or
overweight persons; Weight
loss or dieting
- Adolescents, 14 through 18 years. *See also*
Puberty
- bone health, 53–54, 195, 202–208, 218,
226, 280
- calcium
- absorption, 39, 265
 - accretion, 61, 269
 - balance, 58, 61
 - deposition, 53–54
- DRI, 7, 349, 351, 352, 354–355, 393–
394, 464, 1104, 1108, 1114
- estimated intake, 465, 466, 467, 480
 - retention, 268
- DRI development, 24, 385–387, 393–394,
445
- EARs, 7, 9, 349, 351, 354–355, 385, 387,
393, 394, 464, 469, 1104–1105
- elements, 1108–1109, 1114–1115
- growth spurts, 8, 24, 39, 53, 354, 421
- lactation, 7, 57, 257, 282, 283, 349, 361,
362, 363, 393, 394, 424, 446,
464, 469
- macronutrients, 1110–1111
- multiple sclerosis and serum 25OHD,
173
- pregnancy, 56, 57, 250, 257, 278, 361,
362, 393, 394, 424, 446, 469
- RDAs, 7, 9, 349, 351, 354–355, 385, 387,
393, 394, 464, 469, 1106–1110
- ULs, 7, 9, 419, 420, 421, 441, 445, 464,
469, 1112–1115
- vitamin D, 9, 95, 385–387, 393–394, 441,
445, 469, 470–473, 475, 1106,
1112
- vitamins, 1104–1105, 1112–1115
- water, total, 1110

*Appendixes B through K (pp. 537-1074) are not included in this index.

- Adults, 19 through 30 years
- bone health, 218, 242, 270, 382–383, 384
 - calcium, 7, 39, 54, 269, 349, 355, 421–424, 464, 465, 466, 467, 1104, 1108, 1114
 - DRI development, 24, 355–356, 387–389, 393–394, 421–422, 423–424, 443–445
 - EARs, 7, 9, 349, 355, 387–388, 389, 393, 394, 464, 469, 1104–1105
 - elements, 1108–1109, 1114–1115
 - macronutrients, 1110–1111
 - RDAs, 7, 9, 349, 355, 387–388, 389, 393, 394, 464, 469, 1106–1110
 - ULs, 7, 9, 421, 423, 443, 445, 464, 469, 1112–1115
 - vitamin D, 9, 95, 387–389, 393–394, 443–445, 469, 470–473, 475, 1106, 1112
 - vitamins, 1106–1107, 1112–1113
 - water, total, 1110
- Adults, 31 through 50 years
- bone health, 218–219, 242, 382–383, 384
 - calcium, 7, 39, 54–55, 349, 355–356, 421–424, 464, 465, 466, 467, 1104, 1108, 1114
 - DRI development, 24–25, 355–356, 387–389, 393–394, 421–424, 443–445
 - EARs, 7, 9, 349, 355, 387–388, 389, 464, 469, 1104–1105
 - elements, 1108–1109, 1114–1115
 - macronutrients, 1110–1111
 - RDAs, 7, 9, 349, 355, 387–388, 389, 464, 469, 1106–1110
 - ULs, 7, 9, 421, 423, 443, 445, 464, 469, 1112–1115
 - vitamin D, 9, 95–96, 387–389, 393–394, 443–445, 469, 470–473, 475, 1106, 1112
 - vitamins, 1106–1107, 1112–1113
 - water, total, 1110
- Adults, 51 through 70 years
- bone health, 219, 226–234, 235, 382–383, 384
 - calcium, 7, 349, 356–359, 421–423, 463–464, 465, 466, 467, 480–481, 1104, 1108, 1114
 - dementia, 183
 - DRI development, 24–25, 355–356, 389, 421–423, 443–445
 - EARs, 7, 9, 167, 349, 356, 357, 359, 387–388, 389, 392, 393, 394, 464, 469, 1104–1105
 - elements, 1108–1109, 1114–1115
 - macronutrients, 1110–1111
 - RDAs, 7, 9, 349, 356, 357, 359, 387–388, 389, 393, 394, 464, 469, 1106–1110
 - ULs, 7, 9, 421, 423, 443, 445, 464, 469, 1112–1115
 - vitamin D, 9, 389, 392–394, 443–445, 469, 470–473, 475, 1106, 1112
 - vitamins, 1106–1107, 1112–1113
 - water, total, 1110
- Adults, 70+ years. *See also* Elderly population
- bone health, 219, 226–234, 235, 360, 382–383, 384, 439
 - calcium, 7, 349, 356, 359–361, 421–423, 464–465, 466, 467, 1104, 1108, 1114
 - cognitive function, 183, 185–186
 - DRI development, 359–361, 389–392, 443–445
 - EARs, 7, 9, 349, 356, 360–361, 389, 392, 464, 469, 1104–1105
 - elements, 1108–1109, 1114–1115
 - macronutrients, 1110–1111
 - RDAs, 7, 9, 349, 356, 361, 389–390, 392, 464, 469, 1106–1110
 - ULs, 7, 9, 421, 423, 443, 445, 464, 469, 1112–1115
 - vitamin D, 9, 389–392, 439, 443–445, 469, 470–473, 475, 1106, 1112
 - vitamins, 1106–1107, 1112–1113
 - water, total, 1110
- Adverse effects
- calcium, 22, 42, 404, 405–424, 481, 488, 500–501
 - chronic, *vs.* acute toxicity, 404
 - due to nutrient deficiency. *See* Calcium, deficiency; Phosphorus, deficiency; Vitamin D, deficiency
 - ethical issues, 404, 425, 488, 518
 - indicators. *See* Indicators of adverse outcomes for excess intake
 - research needs, 517–518
 - in risk assessment approach to DRI development, 27, 403, 515
 - use in determination of benchmark intake, 17, 418
 - vitamin D, 6, 10, 404, 405, 424–440, 486, 488

- African Americans
 breast-fed infants and vitamin D, 385, 494–495
 calcitriol levels, 260–261, 296
 “calcium economy,” 294, 517
 cardiovascular mortality, 438
 cognitive function, 186
 diabetes, 153
 limited data for DRI development, 347
 multiple sclerosis, 174
 puberty, 24
 serum 25OHD levels
 atherosclerotic plaque, 438, 444
 bone health, 106, 208, 260–261, 295, 298, 439, 493
 effects of skin pigmentation, 374, 493, 494–495
 vitamin D dose–response, 431
 systemic lupus erythematosus, 177
- Africans, 179, 244. *See also* Gambians; Nigerians
- Agency for Healthcare Research and Quality (AHRQ)
 Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, 127, 128
 overview of AHRQ–Ottawa and AHRQ–Tufts reports, 5, 30–31, 97–98, 100, 126–127
- Albumin. *See* Serum albumin
- Alcohol consumption, 64, 140, 143, 230, 434
- Allergies, 169, 496–498
- All-laboratory trimmed mean (ALTM), 109
- Alopecia, 94
- Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC), 147, 415, 436
- Altitude, 105
- Alzheimer’s disease, 183, 185
- Amenorrhea, 502
- American Academy of Dermatology, 495
- American Academy of Pediatrics, 95, 258
- American Dietetic Association, 497
- American Indians, 197, 439
- American Institute for Cancer Research, 415
- Amsterdam Growth and Health Longitudinal Study, 274
- Anemia, 176
- Angiotensin II, 190
- Ankylosis, 174
- Anorexia, 406, 425
- Anti-angiogenic action, 92, 146
- Antibody-based assays, 107, 108, 109, 365
- Anticonvulsants, 87, 504
- Anti-inflammatory action, 92, 146, 184, 517
- Antimicrobial activity, 177, 178, 179, 181
- Antirachitic, 80
- Apoptosis, 77, 92, 140, 143
- Appetite loss, 171–172
- Arrhythmia, 147, 406, 425
- Arsenic, 1114
- Arthralgia, 176
- Arthritis, 176. *See also* Osteoarthritis; Rheumatoid arthritis
- Asian ancestry or Asians, 179, 199, 231, 252, 254, 268, 347, 439. *See also* Chinese ancestry or Chinese; East Asian ancestry; South Asian ancestry or South Asians
- Assay shift and drift, 107–111, 365–366, 460–461
- Asthma, 4, 129, 168–170, 181, 182
- Atherosclerosis, 147, 438, 444
- Atmospheric conditions, 104, 105, 492
- Autism, 4, 129, 182–183
- Autoimmune disease, 4, 5, 78, 91, 170–177, 181–182, 189, 192. *See also* Crohn’s disease; Diabetes (type 1); Inflammatory bowel disease; Multiple sclerosis; Osteoarthritis; Rheumatoid arthritis; Systemic lupus erythematosus

B

- B cells, 91, 170
- Background intake. *See* Benchmark intake
- Balance (calcium). *See* Calcium balance
- Balance (physical), 166
- Beck Depression Inventory (BDI), 187
- Behavior, 182, 184, 186, 295
- Benchmark intake (BI), 17, 418, 440, 519
- Bioavailability, 29, 37, 39, 62–63, 498, 503, 516, 521
- Bioequivalence, 29, 516, 521
- Biomarkers
 for colon carcinogenesis, 144
 of effect, 25–26

- of exposure, 25
- inflammatory, 169–170
- serum 25OHD as biomarker of vitamin D
 - effect, 13–14, 96–97, 263–264, 291, 293, 439, 484, 517, 520
- serum 25OHD as biomarker of vitamin D exposure, 8, 12–13, 96, 99, 293, 363, 381–382, 384, 480, 483
- use of term, 25
- Biotin, 1107, 1113
- Bloating, 37, 497
- Blood pressure, 152, 154, 190. *See also* Hypertension
- Blood volume, extracellular, 407
- Body mass. *See* Lean body mass or lean mass
- Body mass index, 48, 88, 141, 155, 211, 212, 228, 231, 434, 435, 490
- Bone. *See also* Bone health; Skeleton
 - accretion, 46–47, 53, 54, 55, 95, 267–272, 292–294, 351
 - accretion rate, 268, 269–270
 - calcium content at maturity, 54
 - composition, 43–44
 - cortical, 45, 46, 249
 - disorders. *See* Bone, fracture; Bone loss; Osteomalacia; Osteoporosis; Rickets
 - effects of menopause, 47–48, 52
 - formation or mineralization, 44–45, 242, 253, 276–277, 296
 - fracture
 - African Americans, 294, 296, 493
 - BMD, 50, 51, 273, 285–292, 298, 357–358
 - bone loss as risk factor, 48, 60, 359–360
 - calcium supplementation, 285–290, 358, 360, 390–392
 - as indicator of adverse outcomes for excess intake, 6, 405
 - as indicator of nutrient adequacy, 4, 9, 129
 - from military training, 234n.3, 242, 275
 - with osteomalacia, 49, 50, 276–277
 - with osteoporosis, 50–52
 - during pregnancy, 278
 - and serum 25OHD, 195, 215, 226–234, 276, 366–367, 390
 - vegans diet and risk for, 497
 - vitamin D supplementation, 161, 234–235, 236–242, 275, 277, 290–292, 358, 390–392, 438–439
 - maintenance, 283–284, 292–294, 387–388
 - modeling, 45, 53
 - organic matrix (osteoid), 43, 49–50, 62, 94, 275–276
 - pain, 49, 50
 - remodeling, 45–46, 52, 54, 59, 62, 272, 409
 - resorption during lactation, 45n.3, 57, 96, 256, 259, 281–282, 362
 - serum 25OHD levels and. *See* Serum 25-hydroxyvitamin D, bone health
 - trabecular, 45, 46, 249, 270
 - types, 45
- Bone health, as indicator of nutrient adequacy. *See also under specific life-stage groups*
 - African Americans, 208, 294–298
 - bone maintenance, 283–284, 292–294, 387–388
 - effects of adiposity, 490–491
 - integration of evidence, 262–277, 292–294, 370–371
 - lactation, 282–283, 362
 - menopausal status, 209–218, 226, 234–242, 360–361
 - overview, 4, 5, 193–194, 298
 - pregnancy, 277–282, 361–362
 - selection as, 298, 345, 480
- Bone loss. *See also* Osteoporosis
 - African Americans, 296, 298
 - age-related, 52, 54, 55, 95–96, 193, 284, 285, 356, 361
 - calcium balance and, 284–285
 - calcium intake and, 35, 40, 274, 285–292, 356
 - effects of caffeine intake, 64
 - effects of menopause, 47–48, 52, 54–55, 58, 360–361
 - effects of soft drink intake, 64
 - integration of evidence, 262–277, 292–294, 370–371
 - serum 25OHD and, 195
 - spaceflight, 46
 - vitamin D intake and, 96, 292–294
- Bone marrow, 43, 46

- Bone mass**
 calcium intake and, 35, 47, 53, 54, 273–274, 417
 measures associated with calcium, 57–62.
See also Bone mineral content; Bone mineral density; Calcium balance
 peak, 47, 54, 250, 270, 282, 296
 physical activity and, 46, 54, 273, 287, 490–491
 protein intake and, 63
 reduction. *See* Bone loss; Osteoporosis
- Bone mineral apparent density (BMAD)**, 206
- Bone mineral content (BMC)**
 calcium intake and supplementation, 47, 60–62, 219–226, 270–271
 definition, 60
 effects of adiposity, 491
 as indicator of nutrient adequacy, 4, 129
 infant, 195, 196–201
 measurement, 60–62
 postmenopausal women and elderly men, 214, 216
 pregnancy and lactation, 249, 254, 255, 259, 278, 279–280, 283
 serum 25OHD and, 195, 196–205, 218, 219, 393–394
 vitamin D intake and supplementation, 271, 279–280
- Bone mineral density (BMD)**
 African Americans, 295–296
 bone fracture and, 50, 51, 273, 285–292, 298, 357–358
 calcium intake and supplementation, 60–62, 175, 219–226, 270–271, 273–274, 284–290, 392–393
 effects of adolescent pregnancy, 56, 362
 effects of lactation, 57, 256, 257, 259, 282, 283
 effects of menopause, 47–48, 52
 effects of oral contraceptive use, 501–503
 effects of pregnancy, 7, 8, 249, 250, 254, 255, 256, 278, 279–280, 361, 362
 as indicator of nutrient adequacy, 4, 129
 measurement, 60–62
 serum 25OHD and, 195, 196–207, 209, 210–216, 218–219, 226–234, 275, 283, 368–369, 386–387
 use of term, 60
 vitamin D intake and supplementation, 95, 175, 271, 274–275, 279–280, 290–292, 386–387, 392–393
- Boron**, 1114
- Bowel obstruction**, 171. *See also* Inflammatory bowel disease
- Brain development**, 182, 184
- Brain tissue**, 184
- Breast cancer**, 139–142, 435–436
- Breastfeeding**. *See* Human milk; Infants, breast-fed; Lactation
- British Paediatric Association**, 431, 432, 441
- C**
- Caffeine**, 64
- Calcidiol**. *See* 25-Hydroxyvitamin D
- Calcifediol**. *See* 25-Hydroxyvitamin D
- Calcification of soft tissue (calcinosis)**, 6, 44, 61, 88, 405, 406, 409–410, 422, 425, 426
- Calcitonin**, 40, 41, 90
- Calcitriol (1,25-dihydroxyvitamin D)**. *See also* Serum calcitriol
 cancer, 77, 91–92, 139, 146
 cardiovascular disease, 78, 150–151
 extra-renal production, 90, 177, 189, 518–519
 falls and physical performance, 157
 fetal, 252
 formation in the kidney, 77, 84, 90, 481
 functions
 bone formation, 44
 calcium absorption, 35, 38, 39, 89, 253, 260, 264, 267
 calcium excretion, 42
 calcium regulation, 40–41, 89–90, 157, 253
 cytokine production, 189
 glucose transport in the brain, 184
 immune response, 167–168
 phosphorus regulation, 64, 77, 89
 vascular reactivity enhanced by, 148
 gene regulation, 90, 170
 half-life, 97
 interactions with prescription drugs, 504
 during lactation, 91, 259
 multiple sclerosis treatment, 173, 174
 not used as a measure of vitamin D nutriture, 97

- in the placenta, 90, 189
- in pleural fluid, 177
- during preeclampsia, 189
- during pregnancy, 56, 96, 174, 250–251, 252, 254
- rheumatoid arthritis treatment, 175
- rickets and osteomalacia, 49, 94
- systemic lupus erythematosus treatment, 176
- tuberculosis, 178
- use of term, 78
- vitamin D intoxication, 427
- Calcium. *See also* Calcium balance; Serum calcium
 - absorption. *See also* Calcium, bioavailability
 - adolescents, 95, 352
 - African Americans, 260–261, 296
 - children, 352
 - dietary factors, 63–64
 - fractional, 38–39
 - from the gut, and increased risk for nephrolithiasis, 411, 500
 - impaired with rickets, 94
 - as indicator of nutrient adequacy, 4, 129
 - infants, 52, 253, 350, 503, 505
 - methods of measurement, 264–265
 - overview, 38–40
 - during pregnancy or lactation, 242, 249, 250, 253, 256–257, 259, 277, 279, 281–282, 292, 361, 424
 - relationship with vitamin D, 35, 40–41, 143, 279
 - role of calcitriol, 35, 38, 39, 89, 253, 260, 264, 267
 - and serum 25OHD, 213, 257, 259, 264–267, 271, 277, 284, 292, 366, 368, 388–389
 - accretion, 53–54, 269, 350, 351–353, 354, 503. *See also* Bone, accretion
 - adverse effects with. *See* Adverse effects, calcium; Calcium, ULs
 - AIs, 7, 8, 58n.4, 345, 346, 348–351. *See also* Calcium balance, studies; Calcium retention
 - autism, 183
 - bioaccumulation, 35, 43
 - bioavailability, 37, 39, 62–63, 498, 503
 - bone health and, 194, 292. *See also* Supplements, calcium, and bone health
 - cancer, 5, 135, 137, 139, 140, 141, 143, 144–145, 147, 414–416
 - cardiovascular disease, 148, 149
 - cognitive function, 186
 - deficiency, 35, 40, 48–50, 243–248, 254, 271, 386
 - depression, 188
 - diabetes, 155, 156
 - DRIs
 - adolescents, 7, 351, 352, 354–355, 1104, 1108, 1114
 - adults, 7, 355–361, 1104, 1108, 1114
 - background of current report, 346
 - children, 7, 351, 352, 353–355, 1104, 1108, 1114
 - infants, 7, 348–351, 1104, 1108, 1114
 - in IOM 1997 report, 16, 58–60, 61, 346, 350, 351, 404
 - lactation, 7, 361, 362, 1104, 1108, 1114
 - pregnancy, 7, 361–362, 1104, 1108, 1114
 - summary tables, 7–8, 349, 464, 1104, 1108, 1114
 - EARs. *See also* Calcium, AIs
 - and accretion/retention, 58n.4, 268, 272, 292
 - adolescents, 7, 351, 354, 356, 357, 359, 1104
 - adults, 7, 355, 356, 357, 359, 360–361, 1104
 - children, 7, 351, 353, 354, 1104
 - lactation, 7, 9, 349, 361, 362, 464, 1104
 - pregnancy, 7, 9, 349, 361, 362, 464, 1104
 - summary tables, 7, 349, 464, 1104
 - elemental, 37
 - excretion
 - adolescents, 95, 352
 - children, 352
 - dietary factors, 63–64
 - infants, 8
 - during lactation, 256, 257, 282
 - overview, 41–42
 - postmenopausal women, 55
 - during pregnancy, 189, 250
 - reduction with diuretics, 407

- relationship with calcium intake, 42, 256, 257, 413–414
- relationship with hypercalciuria, 406–407
- by route, 38, 61, 352
- food sources of, 36, 62–63, 413, 466, 497, 498
- homeostatic regulation, 35, 40–41, 49, 56, 84, 89–90, 153, 157, 253
- in human milk, 39, 52–53, 56, 57, 256, 257
- intake. *See* Calcium intake
- interactions with other nutrients. *See* Calcium interactions
- ionized, 35, 43, 56, 250, 257, 424
- during lactation, 7, 8, 45n.3, 56–57, 256–257, 362
- metabolism, 35, 38–42, 43, 56. *See also* Calcium balance
- mobilization or transport, 153, 177–178, 249, 254, 356, 361
- physiological role, 35, 42–52, 157, 184
- during pregnancy, 7, 189, 190, 242, 249–250, 361–362
- RDAs, 7, 272, 292, 351, 353, 354, 355, 356, 357, 359, 361, 1108
- retention. *See* Calcium retention
- rheumatoid arthritis, 175
- sources, 36–37
- supplements. *See* Supplements, calcium
- through the life stages, 7–8
- ULs, 7, 8, 418–420, 421–424, 464, 488, 500–501, 1114–1115
- umbilical cord level, 251, 254
- units of measurement, 31
- Calcium-alkali syndrome, 407–409, 418, 422, 423
- Calcium balance. *See also* Calcium, homeostatic regulation
 - adolescents, 58
 - adults, 355
 - bone remodeling and, 45–46, 272
 - definition, 57
 - estimation methods, 58, 62
 - as indicator of nutrient adequacy, 4, 129
 - infants, 58
 - models, 58–60
 - negative, 284–285
 - neutral, 272–273, 285, 292
 - outcomes, 58
 - during pregnancy or lactation, 249, 277–278, 282, 362
 - regulated by calcitriol. *See* Calcitriol, functions, calcium regulation
 - studies, 57–60, 58n.4, 350, 351, 352
- Calcium bicarbonate, 43, 407
- Calcium carbonate, 37, 63, 407, 408, 417. *See also* Supplements, calcium
- Calcium citrate, 37, 43, 63, 417. *See also* Supplements, calcium
- “Calcium economy,” 294–298, 517
- Calcium glucoheptonate, 37n.2
- Calcium gluconate, 37n.2
- Calcium hydroxyapatite, 35, 37n.2, 43, 44–45
- Calcium intake. *See also* Supplements, calcium
 - absorption of lipids and, 148
 - assessment
 - approach, 462–463
 - Canadian estimated, 465–468
 - Canadian surveys, 461–462
 - estimates from national surveys, 10, 458–460
 - from food sources only, 465, 466
 - summary, 477, 480–481
 - U.S. estimated, 463–465, 466
 - water, 36
 - assumption of adequacy for vitamin D
 - DRI, 347–348
 - bone health and
 - BMC/BMD, 47, 60–62, 175, 195, 219–226, 270–274, 285–290, 392–393
 - bone accretion, 47, 53–54, 292
 - bone loss, 35, 40, 274, 356
 - bone mineralization, 276
 - dose–response relationship, 360
 - during pregnancy, 278–279
 - skeletal recovery after weaning, 57, 256–257, 258, 282, 283, 285
 - cancer, 144–145, 146, 147, 414–416
 - cardiovascular disease, 148
 - diabetes, 155, 156
 - excess, 37, 42, 150, 517–518. *See also* Indicators of adverse outcomes for excess intake
 - excretion of calcium and, 42, 414
 - falls and physical performance, 157
 - inadequate. *See* Calcium, deficiency
 - infants, daily, 53, 349, 350–351

- for neutral calcium balance, 58, 273, 285
 - plateau intake, 58
 - preeclampsia and pregnancy-induced hypertension, 189, 190, 250
 - relationship with calcium absorption, 38–39, 56
 - relationship with calcium retention, 269
 - rheumatoid arthritis, 175
 - systemic lupus erythematosus, 176
- Calcium interactions
 - foods and food components, 62–64
 - iron, 6, 37, 405, 416–417
 - magnesium, 37
 - prescription drugs, 422
 - vitamin D, 5, 6, 35, 60, 136, 358, 360, 369, 388, 484, 517
 - zinc, 6, 37, 405, 417
- Calcium lactate, 37n.2
- Calcium retention
 - adolescents, 53–54
 - bone mass measurements, 61–62
 - calcium intake and, 58–60, 269, 270
 - children, 268, 353
 - effects of dietary protein, 63
 - infants, 350, 503
 - integration of evidence, 292
 - plateau intake, 58
 - race considerations, 296, 297
 - regression modeling, 58
- Canada
 - calcium intake assessment, 37, 465–468
 - changes in diet of indigenous Canadian populations, 11, 498–500
 - compared with the U.S., 474, 476–477
 - national intake surveys, 10–11, 110–111, 457–458, 461–462, 521
 - Recommended Nutrient Intakes, 15
 - use of DRIs, 15
 - vitamin D
 - deficiency, 13–14, 486–488, 494
 - in formula, 81
 - intake assessment and serum 25OHD levels, 10–11, 110–111, 474–477, 478
 - in milk, 79
 - supplementation, 81
- Canadian Community Health Survey (CCHS), 461, 467, 474, 475
- Canadian Food Inspection Agency (CFIA), 79
- Canadian Health Measures Survey (CHMS), 462, 474, 476, 478, 499
- Canadian Institute for Health Information, 461
- Canadian Multicentre Osteoporosis Study, 270
- Canadian Nutrient File (CNF), 462
- Cancer/neoplasms. *See also specific histological sites*
 - calcitriol and, 77, 91–92, 139
 - calcium and, 136, 137, 139
 - as indicator of adverse outcomes for excess intake, 6, 405
 - as indicator of nutrient adequacy, 4, 5, 129, 134–139
 - overview, 134, 135–136
 - serum 25OHD and, 138, 139
 - vitamin D and, 91–92, 135–139, 486
- Cancer Prevention Study II Nutrition Cohort, 142, 414, 436
- Carbohydrate, 83, 1104, 1110, 1111
- Carcinogenesis, 91–92, 135, 143, 144
- Cardiovascular diseases
 - calcitriol and, 78, 150–151
 - calcium and, 148, 149, 150, 407, 410, 481
 - as indicator of adverse outcomes for excess intake, 6, 405
 - as indicator of nutrient adequacy, 4, 5, 129
 - mortality, 148, 149, 150, 438
 - overview, 147–148
 - serum 25OHD and, 148–149, 150–152, 437–438
 - vitamin D and, 88, 148, 149, 425, 426, 437–438
- Carotenoids, 1113
- Cartilage, 44, 48, 94, 174, 175
- Caucasian ancestry
 - calcium accretion, 268–269
 - puberty, 24
 - serum 25OHD levels, 101, 103, 104, 155, 173, 174, 203, 205–206, 211–213, 215, 216
- Celiac disease, 254
- Cell cycle, 91, 140, 143, 146
- Cell differentiation, 77, 91, 140, 143, 146, 157, 176
- Cell proliferation, 77, 90, 140, 146, 157
- Centers for Disease Control and Prevention (CDC), 420, 460, 477
- Cerebrovascular disease, 147
- Cesarean section, 192

- Children, ages 1 through 3 years
 bone health, 218, 382–383, 384, 386
 calcium, 7, 61, 268, 349, 351, 352, 353, 413–414, 420, 463, 464, 465, 466, 467, 1104, 1108, 1114
 DRI development, 23, 385–387, 445
 EARs, 7, 9, 349, 351, 353, 385, 387, 464, 469, 1104–1105
 elements, 1108–1109, 1114–1115
 growth rate, 23
 macronutrients, 1110–1111
 RDAs, 7, 9, 349, 351, 353, 385, 387, 464, 469, 1106–1110
 ULs, 7, 9, 420, 441, 445, 464, 469, 1112–1115
 vitamin D, 9, 95, 169, 385–387, 441, 445, 469, 470–473, 475, 1106, 1112
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Children, ages 4 through 8 years
 bone health, 195, 202–208, 218, 382–383, 384, 386
 calcium, 7, 47, 53, 61, 265, 268, 349, 351, 353–354, 385, 387, 464, 465, 466, 467, 1104, 1108, 1114
 DRI development, 24, 385–387, 445
 EARs, 7, 9, 349, 351, 385, 387, 464, 469, 1104–1105
 elements, 1108–1109, 1114–1115
 macronutrients, 1110–1111
 RDAs, 7, 9, 349, 351, 354, 385, 387, 464, 469, 1106–1110
 ULs, 7, 9, 420, 421, 441, 445, 464, 469, 1112–1115
 vitamin D, 9, 95, 169, 385–387, 441, 445, 469, 470–473, 475, 1106, 1112
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Children, ages 9 through 13 years
 bone health, 53–54, 195, 202–208, 218, 226, 280
 calcium, 39, 53–54, 265, 354–355, 386, 417, 465, 466, 467, 1104, 1108, 1114
 DRI development, 24, 354–355, 385–387, 445
 EARs, 7, 9, 349, 351, 464, 469
 elements, 1108–1109, 1114–1115
 macronutrients, 1110–1111
 RDAs, 7, 9, 349, 351, 464, 469, 1106–1110
 ULs, 7, 9, 419, 420, 421, 441, 445, 464, 469, 469, 1112–1115
 vitamin D, 9, 385–387, 441, 445, 469, 470–473, 475, 1106, 1112
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Chills, 180
 Chinese ancestry or Chinese, 188, 216, 228, 268
 Chloride, 1109, 1115
 Cholecalciferol. *See* Vitamin D₃
 Cholestasis, 505
 Cholesterol, 83, 84, 148, 434, 435, 1111
 Choline, 1107, 1113
 Chondrocytes, 44, 175
 Chromium, 1108, 1114
 Chronic disease and DRI development, 2, 5, 16, 28, 486, 489. *See also specific diseases*
 Chylomicrons, 83–84, 106
 Clothing, 81, 100, 105, 494
 CLUE, 436
 Cognitive function, 4, 129, 183–186, 188
 Collagen, 43, 44, 175
 Colorectal cancer/colon polyps, 135, 142–144
 Communication deficits, 182
 Competitive protein-binding assays (CPBAs), 107, 108, 109
 Computed tomography, 61, 62
 Constipation, 6, 37, 405, 417, 422
 Contraceptives, oral, 11, 501–503
 Convulsions, 94
 Copper, 1105, 1108, 1114
 Cord, blood chemistry, 192, 251, 252, 254, 281
 Coronary artery disease, 147
 Corpuscular indexes, 417
 Cramping, 171
 Craniotabes, 255, 280
 C-reactive protein, 152, 435
 Creatinine, 176, 406, 408, 409, 428–429, 434
 Crohn's disease, 4, 129, 171–173
 Cross-cultural differences. *See* Race/ethnicity
 Cubilin-megalin receptor system, 88
 Cut-point, 13, 14, 144, 462, 480, 486–488, 522
 CYP enzymes, 84–87, 90
 Cytochrome P450, 77, 85
 Cytokines, 175, 189, 491

D

- Dairy products
autism, 183
calcium, 36, 62, 414–415
cancer risk, 142, 146, 414–415
constipation from, 417
diabetes, 155
lactose intolerance or cow's milk allergy, 496–498, 501
protective compound against kidney stones, 500
vitamin D–fortified, 79–80, 431–432, 497
- Data
assignment of “race” in study design, 295
associations *vs.* causal or predictive relationships, 263–264, 480, 485, 517
challenges
graded doses, 12, 484, 515, 519
isolation of effects of single nutrient, 5, 6, 11, 12, 35, 346, 485
limited or incomplete. *See* Research needs; Uncertainties
pre-existing disease conditions, 406, 422
standardization, 109, 516, 521
statistical analysis/synthesis
methodology, 158–159, 519
extrapolation
from animal studies, 96
from EAR and UL values, 27
from observed data to general population, 404
from one life stage to another, 23, 24, 346, 355, 393
inconsistency in measured outcomes, 181
interpolation, 354, 423
observational, 22, 130
postmortem, 275, 350, 367, 388
quality, and hierarchy of study design, 127, 128, 130, 131–132, 133
scaling, 29, 346
uncertainties in analysis, 158–159
uncertainties in collection, 11–12, 167
weighted, 519
- Decision making, 18–19, 26
- 7-Dehydrocholesterol, 75, 81, 95, 100, 101, 104, 496
- Dementia, 4, 183–186
- Deoxyribonucleic acid (DNA), 105, 143
- Depression, 4, 129, 186–188
- Dermatitis, 168
- Diabetes (type 1), 4, 5, 170–171, 189, 192, 255
- Diabetes (type 2), 4, 5, 129, 151, 152–156
- Diarrhea, 171, 497
- DiaSorin, 110–111, 111n.12, 476, 476n.17–18
- Dietary intake. *See also* Supplements; *specific nutrients*
assessment. *See* Intake assessment, dietary effects on asthma, 168
fat, 83, 148, 168, 498, 1110, 1111
fiber, 62, 417, 1110
of indigenous Canadian populations, 11, 498–500
of peoples in the far north, 492
protein, 63, 1104, 1110, 1111
research needs, 521
self-reported, 459, 460, 497
total intake, 457, 459, 474, 483
tuberculosis, 179
use of term, 457
vegetarian or vegan, 11, 63, 179, 496–498
- Dietary Reference Intakes (DRIs)
AI and, 345
background, 15–16, 18
calcium. *See* Calcium, DRIs
components, 3, 15–16, 20. *See also* Adequate Intake; Estimated Average Requirements; Recommended Dietary Allowance; Tolerable Upper Intake Levels
criteria for, 30–31, 485
decision making, 18–19, 26
definitions, 19–22
development
and chronic disease, 2, 5, 16, 28, 486, 489
IOM initiative, 15–16, 91
and public health. *See* Public health considerations, in DRI development
rationale and assumptions, 16–17, 347–348, 351, 369, 370, 385. *See also* Sun exposure, DRI development, assumption of minimal
risk assessment in, 17, 18, 26–29, 30, 32, 345, 403, 481–482, 488–490, 514–516

- EAR and, 2, 17, 22–23, 294
 elements, 1108–1109, 1114–1115
 extrapolation. *See* Data, extrapolation
 framework, 17–19, 488
 IOM committee. *See* Institute of
 Medicine, committee
 macronutrients, 1110–1111
 measures. *See* Indicators of adverse
 outcomes for excess intake;
 Indicators of nutrient
 adequacy
 overview, 7, 12, 18–19, 23–25, 457, 458,
 479–481
 RDA and, 23, 345
 total water, 1110
 uses, 2, 19–20, 22–23
 vitamin D. *See* Vitamin D, DRIs
 vitamins, 1106–1107, 1112–1113
- Dietary Reference Intakes for Calcium,*
Phosphorus, Magnesium, Vitamin
D, and Fluoride (IOM, 1997)
 calcium, 16, 58–60, 61, 346, 350, 351,
 404, 416, 420–421
 ULs, 404, 420–421
 vitamin D, 9, 16, 97, 346, 404, 425, 487
- Dieting. *See* Weight loss or dieting
- Dietitians of Canada, 497
- 1,25-Dihydroxyvitamin D. *See* Calcitriol
- 24,25-Dihydroxyvitamin D, 78, 86, 109, 504
- Diuretics, 407, 409
- Dose–response relationships
 calcium intake, 269, 360
 intake–response assessment, 17, 28–29,
 31, 403, 418–424, 440–446,
 515–516, 519–520
 public health approach *vs.* medical
 approach, 482, 521
 research needs, 12, 159, 346, 359, 360,
 482, 519–520
- serum 25OHD
 and bone health, 364, 366
 and cardiovascular disease, 148, 149,
 437–438
 and vitamin D, 98, 364–365, 381, 431,
 439
- vitamin D
 and bone health, 159–160, 161, 167,
 291, 363, 364, 365–383, 390
 and colorectal cancer, 145
 and serum 25OHD levels, 98, 364–
 365, 381, 431, 439
 and type 1 diabetes, 171
- Dual-energy X-ray absorptiometry (DXA),
 56, 57, 61–62, 199–201, 205–
 206, 210–216, 229, 231, 233
- Dyslipidemias, 152
- Dysthymic disorder, 186, 187
- ## E
- East Asian ancestry, 101, 103
- Eating disorders, 406, 407, 425
- Eczema, 168, 169, 192
- Elderly population. *See also* Adults, 70+ years
 bone health and serum 25OHD, 209–
 218, 226–234, 496
 cognitive function, 183–186
 diabetes, 154
 falls, 157, 160–161, 166
 indoor environment or institution, 11,
 37, 241, 496
- Elements, 1108–1109, 1114–1115
- Emesis (vomiting), 407, 409
- Encephalomyelitis, 173
- Endocrine system, 35, 40–41, 84, 89, 153,
 156
- Endpoints, 25, 158, 263, 489, 505
- Energy metabolism, 24
- Epidemiological studies, 63, 131, 132, 135,
 145, 176–177, 185, 278, 361
- Epidémiologie de l’Ostéoporose (EPIDOS),
 185
- Ercalcitriol, 78
- Ergocalciferol. *See* Vitamin D₂
- Estimated Average Requirements (EARs).
See also specific nutrients
 calcium. *See* Calcium, EARs
 coefficient of variation, 21
 cut-point method, 462, 480, 486–487
 definition, 3, 20, 482
 development, 2, 8–9, 20–21, 26
 DRI and, 2, 17, 22–23, 294
 of females. *See* Females, EARs
 during lactation. *See* Lactation, EARs
 of males. *See* Males, EARs
 during pregnancy. *See* Pregnancy, EARs
 RDA and, 2, 3, 20, 21, 23, 369
 selection of indicators of nutrient
 adequacy, 27–28, 31, 125–127,
 129, 130–134, 298–299
 serum 25OHD level and, 294
 summary table, 1104–1105
 throughout the life cycle. *See under specific*
life stages

uses, 3
 vitamin D. *See* Vitamin D, EARs
 Estonians, 101, 102
 Estradiol, 42, 55, 213, 256, 501
 Estrogen, 24, 48, 54–55, 62, 96, 285, 287,
 490, 501–503
 Ethical considerations, 404, 425, 488, 504,
 518
 Ethinyl estradiol. *See* Contraceptives, oral
 Ethnic background. *See* Race/ethnicity
 Etiology, 5, 134, 187, 406, 426–427, 486
 European ancestry, 101, 374, 375
 European Prospective Investigation into
 Cancer and Nutrition (EPIC),
 145
 Exercise. *See* Physical activity

F

Falls and physical performance. *See also*
 Physical activity
 calcium, 157, 158, 162–165
 definition and assessment challenges,
 158
 as indicator of adverse outcomes for
 excess intake, 6, 161, 405
 as indicator of nutrient adequacy, 4, 5,
 129, 156–167
 overview, 156–157, 194
 serum 25OHD, 157, 158–160, 162–165,
 166, 167, 226, 439
 vitamin D, 157–165, 167, 438
 Far Easterners, 230, 244
 Fat, dietary, 83, 148, 168, 498, 1110, 1111
 Fatigue, 186, 406
 Females. *See also* Gender differences;
 Women
 EARs, 7, 9, 349, 363, 464, 469, 1104–1105
 elements, 1108–1109, 1114–1115
 macronutrients, 1110
 RDAs, 7, 9, 349, 363, 464, 469, 1106–1110
 serum 25OHD, 202, 476
 ULs, 7, 9, 419, 441, 464, 469, 1112–1115
 vitamin D intake assessment, 470–473,
 475
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
 Fetus
 asthma, 168
 BMC/BMD, 279–281. *See also* Pregnancy,
 bone health, BMC/BMD

brain development, 184
 calcium needs, 55–56, 242, 249, 281, 361,
 393–394
 and non-skeletal reproductive outcomes,
 192
 phosphorus, 56, 252
 preeclampsia, 189
 PTH, 252
 skeleton development, 55–56, 57, 193,
 242, 249, 393–394
 vitamin D, 96, 169, 182, 252–256, 279–
 280, 393–394
 Fever, 180
 Fiber, dietary, 62, 417, 1110
 Fibroblast-like growth factor-23 (FGF23),
 77, 84, 85, 90, 515, 518
 Finnish peoples, 169, 191, 203, 206, 225,
 232, 372, 374, 376, 383, 437,
 492
 First Nation peoples, 11, 245, 462, 498–500
 Flatulence, 37, 417, 497
 Fluoride, 16, 1108, 1114
 Folate, 1105, 1107, 1113
 Food and Drug Regulation, 79
 Food and Nutrient Database for Dietary
 Studies 3.0 (USDA), 459
 Food composition databases, 36, 80, 458,
 459
 Food sources. *See also* Fortified foods
 of calcium, 36, 62–63, 413, 466, 497,
 498
 calcium intake estimates from, 465, 466
 of vitamin D, 79–81, 498
 vitamin D intake estimates from, 470,
 474, 475, 476
 Forest plot, 209, 217, 234, 238–240
 Formula, infant, 52, 80–81, 95, 431, 503,
 505
 Fortified foods, 1, 15, 22, 36, 62, 79–80,
 431–432, 466, 497, 498. *See also*
 Formula, infant
 Fracture. *See* Bone, fracture
 Framingham Offspring Study, 148, 149, 437
 Framingham Osteoporosis Study, 63
 Fructose, 415

G

Gambians, 53, 249, 256, 257, 259, 278
 Gas chromatography, 109
 Gastroenteritis, 180

- Gender differences, 95, 101, 139, 354, 437.
See also Men; Women
- Genetics
 assignment of “race” in study design, 295
 asthma, 168, 170
 bone mass, 46, 55
 calcitriol gene expression, 146
 calcium content of human milk, 53
 genetic variation and serum 25OHD as biomarker, 517
 rickets, 49, 94, 254
 systemic lupus erythematosus, 176
 vitamin D, 140. *See also* *Vdr* gene; *Vdr*-null mice
- GLA protein, 44
- Glomerular filtration rate (GFR), 55, 411, 412, 426, 428–429, 435
- Glossary, 527–536
- Glucocorticoids, 62
- Glucose, 153–154, 155, 156, 170, 184, 505
- Greeks, 273, 274
- Growth factors, 43, 44, 91, 143, 146, 184.
See also Fibroblast-like growth factor-23; Vascular endothelial growth factor
- Growth hormone, 53
- Growth rate, 6, 23, 405, 420, 431, 495
- H**
- Handgrip strength, 166
- Hazard characterization, 26, 27, 28–29, 345, 403, 514, 515–516, 519–520, 522
- Hazard identification, 26, 27–28, 30, 125, 403, 514, 515, 516–519, 522
- Hazard ratio, 137, 227, 286, 358, 412, 433
- Health Canada, 94–95, 461, 476
- Health Professionals Follow-up Study (HPFS), 138, 147, 148, 151, 415, 436
- Heart failure, 147, 150–151, 166
- Height, 140, 202, 462, 495. *See also* Growth rate
- Hematocrit, 417
- Hemoglobin, 155, 417
- Hippocampal cells, 184
- Hispanics, 104, 174, 347, 374, 493, 494, 495
- Histamine-2 blockers, 37, 407
- Hormone replacement therapy (HRT), 210, 213, 286, 358, 393, 501–503
- Human milk. *See also* Infants, breast-fed; Lactation
 calcium content, 8, 39, 52–53, 56, 57, 256, 257, 259, 281–282, 349, 351, 394, 503
 intake volume per day, 53, 349, 351
 as optimal source of nutrients, 348–349
 phosphorus in, 503
 25OHD in, 80, 94, 257–258
 vitamin D content, 80, 94, 96, 257, 494
 volume produced, 282
- Hydroxyapatite. *See* Calcium hydroxyapatite
- 1 α -Hydroxycholecalciferol, 157
- 1 α -Hydroxylase
 in the brain, 184
 calcitriol formation and, 35, 56, 77, 84, 97
 expressed in extra-renal tissues, 77
 expressed in the colon and rectum, 143
 expressed in the kidney, 35, 42, 56, 251, 252
 expressed in the placenta, 189, 251, 252
 with granulomatous diseases, 431
 impaired with vitamin D–dependent rickets type 1, 94
 induced by PTH, 35, 56, 84
 with inflammatory disease, 177–178
 molecular cloning, 177
 suppression by FGF23, 85
 vitamin D₂ and, 93
- 24-Hydroxylase, 85, 86
- 25-Hydroxylase, 77, 84, 93
- 1 α -Hydroxylase-null mice, 253, 260
- 25-Hydroxyvitamin D (25OHD). *See also* Serum 25-hydroxyvitamin D
 assays for, 107–111, 476, 484, 516, 521
 discovery, 107
 formation in the liver, 77, 85
 in human milk, 80, 94, 257–258
 lifetime, 86
 during pregnancy, 192, 252
 relationship with calcium absorption, 95, 347
 use of term, 78
 vitamin D intoxication, 89, 427–430
- Hypercalcemia
 calcification associated with, 406, 409–410
 diseases associated with, 91, 177
 excess vitamin D intake and, 88, 406, 425, 426–430, 431

- as indicator of adverse outcome for
 - excess intake, 6, 405, 406, 425, 440, 443, 501
 - in IOM 1997 report, 404
 - renal insufficiency with, 407–409, 410
 - toxic condition, 140, 174, 406–407
 - Hypercalciuria**
 - increased risk for nephrolithiasis with, 411, 501
 - as indicator of adverse outcome for excess intake, 6, 405
 - in IOM 1997 report, 404
 - during pregnancy, 56, 250, 277, 278–279, 424, 501
 - with sarcoidosis, 91
 - toxic condition, 406–407
 - Hyperglycemia**, 155
 - Hyperparathyroidism**, 48, 49, 55, 95–96, 111, 296, 409
 - Hyperphosphatemia**, 407, 409n.1
 - Hypertension**, 4, 5, 129, 147, 151, 189–191, 435. *See also* Cardiovascular diseases
 - Hypervitaminosis D**, 88, 93, 109, 425, 440, 481, 518
 - Hypocalcemia**, 48, 49, 94, 184, 251, 253, 254, 256
 - Hypocalciuria**, 189
 - Hypoparathyroidism**, 201, 409
 - Hypophosphatemia**, 48, 253, 407
 - Hypovitaminosis D**, 259, 283
- I**
- IARC studies**, 141, 143–144, 145
 - Immune function**, 78, 91, 167–168, 170, 176, 177, 180
 - Immune responses**, 4, 5, 129, 167–182
 - Immunoglobulins**, 91, 169–170, 176, 497
 - Indian ancestry or Indians (East Indian)**, 207, 245, 493–494
 - Indians (North American)**. *See* American Indians; First Nation peoples
 - Indicator, use of term**, 25
 - Indicators of adverse outcomes for excess intake**, 28, 403, 405–418, 422, 424–440
 - Indicators of frailty**, 434
 - Indicators of nutrient adequacy**. *See also specific indicators, nutrients, and life stages*
 - data examination of, 3, 5–6
 - data quality, hierarchy of study design, 127, 128, 130, 131–132, 133
 - process, 25–26, 27–28, 130, 132–134, 135
 - review and selection, 27–28, 31, 125–127, 129, 130–134, 298–299, 515, 516–519
 - summary tables, 4, 129
 - Indoor environments and institutionalized persons**, 37, 241, 496
 - Infants, 0 to 12 months**. *See also* Formula, infant; Human milk
 - ages 0 to 6 months, 7, 23, 39, 109, 192, 218, 251–252, 268, 348, 349, 350, 383, 385, 386, 418, 419–420, 440, 441, 442, 464, 469, 1106–1110, 1112–1115
 - ages 6 to 12 months, 7, 23, 348, 349, 350–351, 383, 385, 386, 418, 420, 441, 442, 464, 469, 1104–1110, 1112–1115
 - birthweight or length, 192–193, 251–252, 254, 255, 283
 - bone health, 195, 196–201, 251–252, 257–258, 283, 386, 394
 - breast-fed, 39, 52, 94, 201, 348–349, 350, 493, 494–495
 - calcium
 - absorption, 39, 52, 253, 350, 503, 505
 - accretion, 268
 - AIs, 7, 345, 348–351
 - balance, 58
 - bone deposition, 52
 - DRI development, 24, 418–420
 - intake, 52–53, 249, 281–282, 349
 - RDAs, 1108
 - total body, 268
 - ULs, 418, 419, 420, 464, 1114
 - EARs, 1104–1105
 - elements, 1108–1109, 1114–1115
 - formula-fed, 23, 39, 52, 201
 - growth rate, retarded, 6, 405, 431, 495
 - indicators of adverse outcome for excess intake, 6, 405, 431, 495
 - macronutrients, 1110
 - premature, 11, 31, 503–505
 - RDAs, 1106–1110

- ULs, 418, 419, 420, 464, 1112–1115
 vitamin D, 94–95, 96, 258, 383, 385, 431–432, 440–442, 494–495, 1106, 1112
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Infectious diseases, 4, 5, 78, 177–181, 182. *See also* Influenza; Tuberculosis; Upper respiratory infections; Vaginosis
- Inflammation, 175, 180. *See also* Anti-inflammatory action; Asthma; Autoimmune disease; Crohn's disease; Inflammatory bowel disease
- Inflammatory bowel disease (IBD), 4, 37, 171–173
- Inflammatory markers, 169–170
- Influenza, 4, 5, 129, 180–181
- Institute of Medicine (IOM)
 committee
 approach for intake assessment, 462–463
 conclusions about vitamin D deficiency, 13–14, 293, 480, 486–488
 data review for DRI development, 3, 5–6, 16–17, 29–32, 135
 members' expertise, 16
 process, 2
 risk assessment approach for DRI development, 17, 18, 26–29, 30, 32, 125, 345, 403, 479, 488–490, 514–516
 summary of uncertainties and research needs, 483–486, 513–522
- 1997 report. *See Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*
- overview of DRI development, 1, 15–16
 workshops, 2, 97, 127, 404–405, 482
- Institutionalized people, 37, 241, 496
- Insulin, 152, 153, 154–155, 156, 170
- Intake. *See* Calcium intake, assessment; Dietary intake; Intake assessment, dietary; Vitamin D intake, assessment
- Intake assessment
 calcium. *See* Calcium intake, assessment
 dietary, 10–11, 110–111, 457–463, 516, 521
 research needs, 516, 520–521
 in risk assessment approach, 27, 29, 514
 vitamin D. *See* Vitamin D intake, assessment
- Intake–response assessment, 17, 28–29, 31, 403, 418–424, 440–446, 515–516, 519–520
- Interactions. *See* Calcium interactions; Nutrient–nutrient interactions; Vitamin D interactions
- Interferon, 176, 177
- Interleukin 1, 175
- International Unit (IU), 78
- Iodine, 1105, 1108, 1114
- Iowa Women's Health Study, 175
- Iron, 6, 37, 80n.3, 405, 416–417, 418, 1105, 1108, 1114
- J**
- Jadad Score, 127, 128, 196–198, 203–204, 210–211, 236
- K**
- Kidney function. *See* Renal function
- Kidney stones. *See* Nephrolithiasis
- Koreans, 186, 200, 201, 255
- L**
- Labor, obstructed, 192
- Lactation. *See also* Human milk; Infants, breast-fed
 adolescents, 7, 57, 257, 282, 283, 349, 361, 362, 363, 393, 394, 424, 464, 469
 calcitriol, 91, 259
 calcium, 7, 8, 45n.3, 56–57, 256–257, 281–282, 292, 349, 361, 362, 464, 1104, 1108
 DRI development, 24, 362
 EARs, 7, 9, 349, 361, 362, 363, 393, 394, 464, 469, 1104–1105

- elements, 1108–1109, 1114–1115
 macronutrients, 1110
 RDAs, 7, 9, 349, 361, 362, 363, 393, 394, 464, 469, 1106–1110
 serum 25OHD and, 218–219, 283, 394
 twins, 257
 ULs, 7, 9, 419, 424, 441, 446, 464, 469, 1112–1115
 vitamin D, 9, 96, 257–260, 282–283, 363, 393, 394, 441, 469, 1106, 1112
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Lactose, 39, 80n.3, 260, 498, 505. *See also*
 Lactose intolerance
- Lactose intolerance, 347, 496–498, 501
- Lean body mass or lean mass, 166, 202, 204, 490, 491
- Lesions, 144, 175, 176
- Leukopenia, 176
- Life stage. *See also* Adolescents; Adults;
 Children; Infants
 calcium, 7–8, 52–57, 345, 349, 464
 categories, 23–25
 extrapolation of data from one to
 another, 23, 24, 346, 355, 393
 interpolation of data, 423
 research needs, 516–517
 vitamin D, 9, 94–96, 345, 363, 441, 469
- Ligand, 77, 89
- Linoleic acid, 1110, 1111
- α -Linolenic acid, 1110, 1111
- Liquid chromatography (LC), 107, 108–109, 110, 365, 430
- Literature review, 17, 28, 31, 126, 127, 130, 141, 252
- Liver, 77, 83, 84, 85, 86–87, 105, 106, 492, 498
- Longitudinal Aging Study Amsterdam, 166, 434
- Lowest observed adverse effect level
 (LOAEL), 418, 421, 422, 423
- Lowest observed effect level (LOEL), 29
- Lumisterol, 81, 82
- Lupus. *See* Systemic lupus erythematosus
- Lymphadenopathy, 176
- M**
- Macronutrients, 1110–1111
- Macrophage, 44, 90, 91, 175, 177
- Magnesium, 16, 37, 168, 1105, 1108, 1115
- Magnetic resonance imaging (MRI), 185
- Males. *See also* Gender differences; Men
 EARs, 7, 9, 349, 363, 464, 469, 1104–1105
 elements, 1108–1109, 1114–1115
 macronutrients, 1110
 RDAs, 7, 9, 349, 363, 464, 469, 1106–1110
 serum 25OHD levels, 476
 ULs, 7, 9, 419, 441, 464, 469, 1112–1115
 vitamin D intake assessment, 470–473, 475
 vitamins, 1106–1107, 1112–1113
 water, total, 1110
- Malnutrition, 254
- Manganese, 1108, 1115
- Maori peoples, 155
- Mass spectrometry, 107, 108–109, 110
- Melanin. *See* Skin pigmentation
- Men. *See also* Gender differences; Males
 age-related bone loss, 52, 55
 bone health
 BMD, 274, 357
 bone loss, 356
 fractures, 234–242, 356, 359–360, 391, 392
 and serum 25OHD, 209–218, 226–234
 vitamin D and calcium
 supplementation, 157, 162, 234–242, 393
 calcium, 162, 356–357
 cognitive function, 185
 EARs, 356, 357, 359
 falls, 157, 162
 mean age of puberty, 24
 nephrolithiasis incidence rate, 411
 RDAs, 356, 357, 359
 serum 25OHD level and cardiovascular
 risk, 437
- Menarche, 139. *See also* Puberty
- Menopausal status
 age of onset, 356, 359
 bone health, 8, 47–48, 52, 54–55, 209–218, 226, 234–242, 360–361, 392
 calcium absorption, 40
 calcium balance, 58, 285
 cancer risk, 138, 141
 ethinyl estradiol and, 501–503

- Metabolic syndrome, 4, 5, 129, 152–156.
See also Obese or overweight persons
- Methodological considerations. *See also* Data; Indicators of nutrient adequacy
- assay for serum 25OHD, 107–111, 476, 484, 516, 521
- assay shift and drift, 107–111, 365–366, 460–461
- assignment of “race,” 295
- calcium balance studies, 57–58
- compliance, 225, 289, 291
- complications in the course of a study, 130
- cut-point method, 13, 14, 144, 462, 480, 486–488, 522
- flaws, biases, and confounding effects in study design, 130
- IOM committee data review, 17
- IOM committee intake assessment, 462–463, 477
- quality assurance, 109–110
- standardization, 109, 516, 521
- use of new, 489n.1
- Mexican ancestry, 166, 493
- Michaelis-Menten constants, 87
- Microsome, 87
- Middle Eastern ancestry or Middle Easterners, 204, 246, 259, 493–494, 495
- Milk. *See* Dairy products; Formula, infant; Human milk
- Milk-alkali syndrome (MAS), 407. *See also* Calcium-alkali syndrome
- Mini-Mental State Examination for Koreans (MMSE-K), 186
- Models, statistical
- calcium retention, 58, 59–60, 268, 353
- calcium supplement intake, 460
- cognitive function, 185
- dietary intake, 460
- effect of latitude on vitamin D synthesis, 104, 380–383
- effects of seasonal sun exposure, 496
- intake–response assessment, 28
- mixed effect model, 380
- Monte Carlo approach, 460
- public health approach *vs.* medical approach, 482, 521
- serum 25OHD and BMC/BMD, 212, 214
- serum 25OHD and vitamin D intake, 380, 463
- Molybdenum, 37, 1105, 1109, 1115
- Moroccans, 244
- Mortality, 6, 156, 179, 405, 425, 432–435, 438, 444
- Multiple sclerosis (MS), 4, 129, 173–174, 181
- Muscles, 43, 49, 50, 84, 156–157, 180, 184, 202
- Myelin, 173
- Myocardial infarction, 147, 148, 149, 151, 437
- ## N
- National Cancer Institute (NCI), 459, 460
- National Center for Health Statistics (NCHS), 110
- National Council on Skin Cancer Prevention, 495–496
- National Health and Nutrition Examination Survey (NHANES)
- calcium intake and BMD, 273
- First (NHANES I), 458
- overview, 458–459
- post-2000 data, 150, 437, 458–459, 465, 466, 470, 471, 472, 473, 493
- Second (NHANES II), 63, 110–111, 458
- serum 25OHD levels, 169, 365, 404, 405, 460–461
- Third (NHANES III), 56, 57, 110–111, 138, 148–149, 166, 185–186, 257, 274, 433, 434, 435, 438, 458
- National Institute of Standards and Technology (NIST), 110
- National Institutes of Health (NIH), 424, 459, 497, 513, 521
- National Osteoporosis Foundation, 357
- Native Americans. *See* American Indians; First Nation peoples
- Natriuresis, 407
- Nephrocalcinosis, 406, 409, 412
- Nephrolithiasis (kidney stones)
- association with nephrocalcinosis, 409
- as indicator of adverse outcome for excess intake, 6, 405, 422, 423, 500–501
- during pregnancy, 250, 279

risk with excess calcium, 286, 410–414, 422, 481

risk with excess vitamin D, 286, 426

Nerve transmission, 35, 43, 89, 173

Neuroblastoma cells, 184

Neurological manifestations, 176

Neuropsychological functioning, 4, 5, 182–188. *See also* Autism; Cognitive function; Depression

New York University Women’s Health Study, 436

Niacin, 1104, 1107, 1113

Nickel, 1115

Nigerians, 246–248, 265

No observed adverse effect level (NOAEL), 418. *See also* Calcium, ULs; Vitamin D, ULs

No observed effect level (NOEL), 28

Northern Finland Birth Cohort of 1966, 191

Norwegians, 154, 187, 244, 437

Numbness, in the limbs, 173

Nurses’ Health Study (NHS), 141, 142, 155, 177, 412–413, 436

Nutrient–nutrient interactions, 5, 6, 7, 11, 12, 35, 37, 346, 405, 416–417, 485

O

Obese or overweight persons. *See also* Adipose tissue; Adiposity; Metabolic syndrome

bariatric surgery, 88, 106, 518

calcium absorption, 39

challenges with bone mass measurement, 62

definition, 490

diabetes, 154, 155–156

metabolic syndrome, 152

vitamin D storage, 88, 105–106, 156, 490, 518

Organ transplant recipients, 158

Osteoarthritis, 216

Osteoblast, 44, 45, 46, 49, 50, 256, 491

Osteocalcin, 44

Osteoclast, 44, 45, 46, 89, 256, 491

Osteoid. *See* Bone, organic matrix

Osteomalacia

cannot be corrected by increased calcitriol, 49

as indicator of nutrient adequacy, 4, 129

overview, 49–50, 94, 156

during pregnancy, 253

serum 25OHD and, 8, 195, 275, 284, 292, 293, 367, 368, 470–471n.16, 494

Osteopenia, 175, 503

Osteophyte, 61

Osteoporosis

with adolescent pregnancy, 250

African Americans, 294–295, 296, 493

effects of lactation, 57, 256

FDA primary outcome, 167

fracture risk and, 50–52

inclusion in bone health measures, 489

low calcium intake and vitamin D levels, 49

with osteomalacia, 50

postmenopausal, 48, 52

serum PTH as risk factor, 260

serum 25OHD and, 231

Osteoporotic Fractures in Men Study (MrOS), 185, 356, 367

Oxalic acid (oxalate), 62, 411, 413, 498, 500

Ozone, 104, 492

P

Pacific Islanders, 155

Pakistani ancestry or Pakistanis, 202, 209, 218, 244, 275, 493–494

Pancreatic cancer, 425, 436–437, 486

Pancreatic endocrine function, 153, 156

Pancreatic insufficiency, 254

Pantothenic acid, 1107, 1113

Paralysis, 173

Parathyroid gland (PTG), 35, 40, 41

Parathyroid hormone (PTH)

as biomarker for bone resorption, 55, 111

bone health and

African Americans, 296

children and adolescents, 205

fractures, 276, 390

infants, 198

postmenopausal women and elderly men, 210, 214–215, 227

serum 25OHD, 198, 208, 246, 260–262

calcitriol regulation, 77, 84, 85

- calcium and, 35, 38, 40–41, 42, 49, 56, 62, 89, 407
- fetal, 252
- as indicator of nutrient adequacy, 4, 129, 260–262
- multiple sclerosis, 174
- osteomalacia, 50
- vitamin D and, 111, 426, 518
- Parathyroid hormone-related protein (PTHrP), 256, 257
- Parkinson's disease, 158
- Periosteal expansion, 44, 46, 53
- Peripheral artery disease or peripheral vascular disease, 147, 150, 152, 437
- Phosphate, 44, 49, 64, 77, 84, 89–90, 407, 409, 426, 500
- Phosphorus
 - absorption, 64
 - BMD and, 62
 - bone formation, 44
 - calcium regulation, 41, 49
 - deficiency, 44, 48, 50
 - EARs, 1105
 - fetal, 56, 252
 - in human milk, 503
 - in milk with cream, 407
 - RDAs, 1109
 - regulation by calcitriol, 64, 77, 89
 - serum, 40, 41, 50, 77, 90, 407, 426
 - ULs, 1115
- Physical activity. *See also* Falls and physical performance
 - bone fracture and, 286
 - bone mass and, 46, 54, 273, 287, 490–491
 - cancer, 140, 141, 142
 - diabetes, 155
 - serum 25OHD and, 105
 - vitamin D synthesis in the skin, 105
- Physiotherapy, 160–161
- Phytic acid, 62
- Pigmentation. *See* Skin pigmentation
- Placenta, 52, 55, 90, 189, 251, 252
- Pneumonia, 180
- Polynesians, 155
- Polyuria, 406, 425
- Population segments and conditions
 - of interest, 11, 17, 29, 31, 490–505
- Portuguese, 186, 244, 245
- Potassium, 63–64, 1109
- Preeclampsia and pregnancy-induced hypertension, 4, 5, 189–191, 250
- Pregnancy. *See also* Lactation
 - adolescents, 56, 57, 250, 257, 278, 361, 362, 393, 394, 424, 469
 - bone health
 - BMC/BMD, 249, 250, 254, 255, 256, 278, 279–280, 361, 362
 - fracture, 278
 - serum 25OHD and, 192–193, 205, 218–219, 251, 255, 279–280, 281
 - calcium, 7, 8, 39, 55–56, 96, 242, 249–250, 277–278, 279, 292, 349, 361–362, 424, 464, 1104, 1108
 - DRI development, 24, 361–362, 393–394
 - EARs, 7, 9, 349, 361, 362, 363, 393, 394, 464, 469, 1104–1105
 - elements, 1108–1109, 1114–1115
 - hypercalciuria during, 424, 501
 - increase in calcitriol, 90–91
 - macronutrients, 1110
 - multiple sclerosis remission, 174
 - non-skeletal reproductive outcomes, 192–193
 - preeclampsia and pregnancy-induced hypertension, 4, 5, 189–191, 250
 - RDAs, 7, 9, 349, 361, 362, 363, 393, 394, 464, 469, 1106–1110
 - ULs, 7, 9, 419, 424, 441, 446, 464, 469, 1112–1115
 - vitamin D, 9, 96, 169, 182, 192, 193, 250–260, 279–281, 363, 393–394, 441, 469, 1106, 1112
 - vitamins, 1106–1107, 1112–1113
 - water, total, 1110
- Prescription drugs, interactions with, 11, 87, 422, 504, 505
- Profile of Mood States (POMS), 188
- Prohormone, vitamin D as, 75, 84, 481, 484
- Proinflammatory state, 152
- Project VIVA, 169
- Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), 141, 436
- Prostate cancer, 6, 145–147, 405, 414–416, 422, 437
- Protein, dietary, 63, 1104, 1110, 1111
- Proteinuria, 176, 189

- Prothrombotic state, 152
- Proton-pump inhibitors, 37, 407
- Provitamin D. *See* 7-Dehydrocholesterol
- Puberty, 8, 24, 39, 47, 262, 354. *See also*
Adolescents
- Public health considerations
cancer, 134
cardiovascular disease, 147
in DRI development
calcium, 359, 360, 421, 423, 477
overview, 29, 293, 298, 404, 479, 482,
488–489, 522
vitamin D, 370, 388, 420, 440, 442,
445, 483, 485, 488, 494
- ## R
- Race/ethnicity
assignment of “race” in study design, 295
breast-fed infants and vitamin D, 385,
494–495
calcitriol levels, 260–261
“calcium economy,” 294, 517
calcium retention, 296, 297
cardiovascular mortality, 438
clothing and sun exposure, 105, 494
fractures, 439
limited data for DRI development, 347
onset of breast development, 24
relationship between serum 25OHD and
PTH, 260–261
research needs, 347, 516–517
serum 25OHD levels, 101, 103, 104, 106,
174, 260–261, 374, 431, 438,
439, 444, 493
- Radioimmunoassay (RIA), 110–111, 198
- Randomised Evaluation of Calcium and/Or
vitamin D (RECORD), 154
- Recommended Dietary Allowances (RDAs)
applicable population, 21
background, 15
calcium. *See* Calcium, RDAs
defined, 3, 21, 482
development, 3, 8, 9–10, 21
EAR and, 2, 3, 20, 21, 23, 369
elements, 1108–1109
macronutrients, 1110
throughout the life cycle. *See under specific
life stages*
uses, 15
- vitamin D. *See* Vitamin D, RDAs
vitamins, 1106–1107
water, total, 1110
- Recommended Nutrient Intakes (RNIs), 15
- Rectal mucosa cancer, 135
- Renal function
calcitriol formation and, 77, 84, 90, 481
renal failure, 407, 409n.1
renal insufficiency
cardiovascular disease, 426
chronic kidney disease–mineral
disorder, 55
hypercalcemia, 42, 406, 407–409,
410, 425
percent of N. Amer. population with,
406
renal dialysis patients, 91
vitamin D intoxication, 88, 426
- Reproductive outcomes, non-skeletal, 4,
192–193. *See also* Preeclampsia
and pregnancy-induced
hypertension
- Research needs
adverse effects of vitamin D, 424–425
background diet to calculate total level
of intake, 346
calcium intake and BMD, 273
chronic diseases, 5, 486, 489
clinical trials, 5, 12, 22, 135, 404, 486
context, 17, 18–19
dose–response relationships, 12, 159,
346, 359, 360, 482, 484,
489, 519–520. *See also* Sun
exposure, DRI development
ethnic/racial considerations, 347,
516–517
indicator review and selection, 515,
516–519
intake assessment, 22, 516, 520–521
intake response–assessment, 519–520
isolation of effects of single nutrient, 5,
6, 11, 12, 35, 346, 485
long-term data, 12, 425, 485, 518
reproducibility, 26, 109
serum 25OHD, 12, 139, 181, 517, 518,
519, 520, 521
summary, 513–522
sun exposure, 12, 484, 516, 520
vitamin D as a hormone, 12
- Rheumatoid arthritis (RA), 4, 129, 174–175,
177, 189

- Rhinitis, 169
- Riboflavin, 1104, 1107, 1112
- Rickets
 - hereditary vitamin D-resistant (VDDR II), 49, 94, 252, 254, 260, 276
 - as indicator of nutrient adequacy, 4, 129
 - neonatal or vitamin D-deficiency, 75, 252, 254, 256, 280–281
 - premature infants, 503
 - prevention with vitamin D-fortified foods, 79
 - serum 25OHD, 49, 235, 237, 243–248, 271, 293, 366, 368, 386, 470–471n.16, 494
 - vitamin D-dependent (VDDR I), 49, 94, 252, 254, 260, 276
- Risk, use of term, 26
- Risk analysis, basic assumptions, 18–19, 347–348
- Risk assessment
 - definition, 18
 - in DRI development, 17, 18, 26–29, 30, 32, 345, 403, 479, 488–490, 514–516
 - four steps, 27
 - overview, 3
 - population segments and conditions of interest, 11, 490–505
 - role of dietary intake assessment, 457
- Risk characterization, 11, 17, 26, 27, 29, 479
- Risk communication, 18
- Risk management, 18
- S**
- Sarcoidosis, 91, 409
- Saudi Arabians, 251, 259, 283
- Scarring and scar tissue, 171, 173
- Schizophrenia, 182
- School meals, 15, 354
- Scleroderma, 409
- Seasonal affective disorder, 186, 187
- Selenium, 1105, 1109, 1115
- Sensitive populations. *See* Special concerns
- Serum albumin, 215, 229, 249–250, 257, 434, 435
- Serum calcitriol, 38, 78, 150–151, 177, 191
- Serum calcium
 - colorectal cancer, 143
 - decline with rickets, 49
 - diabetes, 153
 - effects of excess vitamin D, 405, 426, 428–429, 430–431
 - hypercalcemia, 38, 406, 408, 426
 - as indicator of adverse outcomes for excess intake, 6, 405
 - during lactation, 257, 424
 - during pregnancy, 56, 249–250, 253
 - regulation, 35, 40–41, 77, 89–90, 426
- Serum 25-hydroxyvitamin D (25OHD)
 - assays for, 107–111, 476, 484, 516, 521
 - asthma, 169–170, 181
 - autism, 183
 - as biomarker
 - of vitamin D effect, 13–14, 96–97, 263–264, 291, 293, 439, 484, 517, 520
 - of vitamin D exposure, 8, 12–13, 96, 99, 293, 363, 381–382, 384, 480, 483, 486–488, 520
- bone health and
 - African Americans, 106, 208, 260–261, 295, 298, 439, 493
 - BMC, 195, 196–205, 210–218
 - BMD, 195, 196–207, 209–218, 275, 368, 386–387
 - bone loss, fractures, osteomalacia, 195, 275
 - calcium absorption, 213, 257, 259, 264–267, 271, 277, 284, 292, 366, 368, 388–389
 - children and adolescents, 195, 202–208, 382–383, 384
 - distribution in healthy populations, 294
- DRI development
 - analysis and outcomes, 263–264, 380–383
 - conclusions, 366–370, 381–382, 486–488
 - integration of evidence, 292–294, 370–379
 - interpretation of data in the literature, 365–366
 - non-linear relationship with vitamin D intake, 12, 99, 379–383, 384, 484
- fractures, 195, 231, 235, 236–237, 291–292, 366–367, 390, 438–439
- infants, 195, 196–201, 257–258, 281, 283

- mineralization, 275–276
- osteomalacia, 195, 275, 284, 292, 293, 367, 368, 470–471n.10, 494
- overview, 4, 5, 129, 193–194
- postmenopausal women and elderly men, 209–218, 226–234
- pregnancy and lactation, 192–193, 205, 218–219, 251, 255, 257–259, 279–280, 281, 283, 393–394
- PTH, 198, 208, 246, 260–262
- rickets, 49, 235, 237, 243–248, 271, 293, 366, 368, 386, 470n.10, 494
- cancer, 5, 138, 139, 140–141, 143–145, 146, 436–437
- cardiovascular disease and hypertension, 148–149, 150–152
- cognitive function, 185–186
- depression, 187–188
- desired level for population median, 8, 470–471n.16
- diabetes, 151, 154–156
- factors affecting, 88, 97–107
- falls and physical performance, 157, 158–160, 162–165, 166, 167
- half-life, 263
- infants, 195, 196–201, 257–258, 281, 283, 504–505
- inflammatory bowel disease and Crohn's disease, 172–173
- insulin sensitivity, 154
- intake assessment process
 - levels for U.S. and Canada, 10–11, 13, 476
 - methodological considerations, 463, 476
 - in national surveys, 460–461, 462, 474, 477–478
 - review of national survey data, 31, 477–478, 480
 - vs.* plasma 25OHD, 461n.10
- interactions with prescription drugs, 504
- mortality, all-cause, 425, 432–435, 444
- multiple sclerosis, 173, 174
- neonatal, 109, 258, 280–281, 283
- population baseline, 99
- preeclampsia and pregnancy-induced hypertension, 189, 190, 191
- public health considerations, 521
- race/ethnicity considerations, 101, 103, 104, 106, 174
- relationship with BMD, 95
- relationship with body fat, 88, 105–106
- relationship with PTH, 111, 260–262
- research needs, 517, 518, 519, 520, 521
- rheumatoid arthritis, 175
- systemic lupus erythematosus, 177
- toxicity, 404, 443–444
- tuberculosis, 178, 179, 180, 494
- uncertainties associated with, 12, 13, 97, 381–382
- units of measurement, 32, 487
- vaginosis, 192
- vitamin D and
 - effects of sun exposure. *See* Sun exposure, relationship between 25OHD and vitamin D
 - effects of supplementation, 98, 106, 179, 180, 243–248, 251–252, 266, 379, 381–382, 426–430, 431
 - intake, 10–11, 97–100, 110–111, 364, 370–383, 386–387, 468–477
 - intake assessment data, 468–477, 484
 - intoxication, 426–430, 443
- Serum 25-hydroxyvitamin D₂ (25OHD₂), 107, 108
- Serum 25-hydroxyvitamin D₃ (25OHD₃), 107, 108
- Serum parathyroid hormone, 111, 174, 260–262
- Serum phosphate, 407, 409
- Serum phosphorus, 40, 41, 50, 77, 90, 407, 426
- Serum vitamin D₃, 104
- Shanghai Women's and Men's Health Studies, 436
- Signal transduction, 43, 93
- Silicon, 1115
- Skeleton. *See also* Bone; Bone health
 - bone types, 45
 - gestational development, 55–56, 57, 193, 242, 249, 281, 393–394
 - three functions, 42–43
 - timeframe for turnover, 45
- Skin cancer, 6, 12, 136, 363, 370, 481, 491, 496
- Skin eruptions, 176

- Skin pigmentation, 101–104, 174, 370, 481, 493–495
- Smoking, 147, 415, 434, 435, 436
- Social withdrawal, 182, 186
- Sodium, 62, 63–64, 168, 1109, 1115
- South Asian ancestry or South Asians, 101, 103, 154, 493–494
- Special concerns
 - limited or incomplete data. *See* Data, challenges; Uncertainties
 - population segments and conditions of interest, 11, 17, 29, 31, 490–505
- Sri Lankans, 244, 493–494
- Stakeholders, 2, 3, 19, 29, 126, 127, 479, 513, 521
- Staphylococcus, 178
- STATA regression analysis software, 159
- Statistics Canada, 461, 467, 475, 476, 477
- Stem cells, 43
- Steroids, 53, 58
- Stroke, 147, 149, 150, 152, 158, 160, 185
- Study of Osteoporotic Fractures, 213, 296
- Sugars, 1111. *See also* Fructose; Glucose
- Sun exposure
 - altitude, 105
 - atmospheric conditions, 104, 105, 492
 - cardiovascular diseases, 148
 - Crohn's disease, 172
 - DRI development
 - assumption of minimal, 8, 98, 364, 370–371, 378–379, 389, 481, 482–483
 - research needs, 12, 484, 516, 520
 - latitude considerations, 11, 98–99, 100, 101, 104–105, 136, 170, 174, 202, 371–383, 477–478, 491–492
 - multiple sclerosis, 173, 174
 - during pregnancy, 254
 - prostate cancer, 147
 - radiation. *See* Ultraviolet A radiation; Ultraviolet B radiation
 - reduced vitamin D synthesis
 - clothing, 105, 494
 - indoor environment, 11, 37, 496
 - skin pigmentation, 11, 100–104, 174, 370, 481, 493–495, 520
 - sunscreen, 11, 105, 370, 495–496, 516, 520
 - relationship between serum 25OHD and vitamin D, 98–105, 172, 187, 364, 370–383, 430, 468, 471–473, 477–478. *See also* Sun exposure, reduced vitamin D synthesis; Sun exposure, skin cancer; Vitamin D, synthesis in the skin
 - seasonal affective disorder, 187
 - seasonal considerations, 100–101, 102, 104, 174, 200, 371, 378–383, 471–473, 478, 484, 492
 - skin cancer, 6, 12, 136, 363, 370, 481, 491, 496, 520
 - type 1 diabetes, 170–171
- Sun protection factor (SPF), 495
- Sunscreen, 11, 105, 370, 495–496, 516, 520
- Supplements
 - calcium
 - adverse effects with, 22, 42, 404, 405–424, 481, 500–501. *See also* Calcium, ULs
 - bioavailability, 63
 - and bone health, 209, 210–211, 217, 218, 219–226, 234–242, 243, 246, 274, 285–290, 358, 360, 391, 417
 - cancer, 137, 139, 141, 142, 144–145, 147, 414–416
 - cardiovascular disease, 149–150
 - diabetes, 153, 154–155
 - falls and physical performance, 158, 162–165
 - during lactation, 256
 - percent of population which takes, 37
 - preeclampsia and pregnancy-induced hypertension, 190, 191, 250
 - rickets, 49, 243–248, 260
 - role in intake assessment, 460, 463–464, 466
 - and serum 25OHD levels, 243, 266
 - with vegan diet, 498
 - dosage issues, 1
 - phosphate, 414
 - self-reported use, 36, 37, 460
 - vitamin D
 - adverse effects with, 6, 10, 404, 405, 412, 427, 486. *See also* Vitamin D, ULs

- and bone health, 196–208, 209–226, 234–235, 236–242, 243–248, 285–286, 290–292, 358, 390–392
 - cancer, 136, 137, 141, 142
 - cardiovascular disease, 148, 149
 - depression, 187–188
 - diabetes, 153–154, 171
 - dosage issues, 81, 106–107
 - effects on serum 25OHD level, 87–89, 98, 106, 179, 180, 243–248, 251–252, 266, 379, 381–382, 426–430, 431, 468, 471
 - falls and physical performance, 157–165, 167, 438
 - and infant birthweight or length, 192, 193, 251–252, 283
 - for infants, 95, 96, 258, 495
 - influenza and upper respiratory infections, 180
 - during lactation, 258
 - preeclampsia, 190
 - during pregnancy, 9, 96, 169, 182, 190, 192, 193, 251–252
 - rheumatoid arthritis, 175
 - tuberculosis, 177, 178–179
 - with vegan diet, 498
 - Surrogates, 8, 25, 144, 145, 264
 - Synovial fibroblasts, 175
 - Synovitis of the joints, 174
 - Systemic lupus erythematosus (SLE), 4, 129, 176–177
- T**
- T cells, 91, 170
 - Tachysterol, 81, 82
 - Teeth, 35, 193
 - Testosterone, 145, 213, 230
 - Tetany, 49, 94
 - Thiamin, 1104, 1106, 1112
 - 3-epi series, 86, 109
 - Threshold effect, 141, 515, 516
 - Thrombogenicity, 148
 - Thyroid gland, 40
 - Toddlers. *See* Children, ages 1 through 3 years
 - Tolerable Upper Intake Levels (ULs), 3, 5–6, 8, 10, 12, 22, 403–405, 1112–1115. *See also* Calcium, ULs; Vitamin D, ULs
 - Total intake. *See* Dietary intake, total intake
 - Transient receptor potential cation channel, vanilloid family member 5 (TRPV5), 42
 - Transient receptor potential cation channel, vanilloid family member 6 (TRPV6), 38, 253
 - Triglycerides, 83, 84
 - Tuberculosis (TB), 4, 5, 91, 177–180, 430, 494
 - Tufts Medical Center Evidence-based Practice Center, 513
 - Turks, 230, 243, 244
 - Tympanotomy tube placement, 181
- U**
- Ulcerative colitis, 172, 173
 - Ulcers, 407
 - Ultraviolet A radiation (UVA), 105
 - Ultraviolet B radiation (UVB), 105, 179, 254, 430, 491–492, 494. *See also* Sun exposure
 - Uncertainties. *See also* Data; Research needs
 - calcium-vitamin D interactions and independent effects, 5, 6, 60, 358, 360, 369, 388, 405, 484
 - in the context of risk assessment, 3, 18, 19, 29
 - in data analysis, 158–159
 - in data collection, 11–12, 167
 - dose–response relationships, 12, 159, 346, 355, 359, 360, 482, 484, 489, 515, 519. *See also* Sun exposure, DRI development
 - due to pre-existing disease conditions, 406, 422
 - meta-regression analysis methods, 158–159
 - methods for serum 25OHD assay, 107–111, 476, 484. *See also* Methodological considerations, assay shift and drift
 - need for long-term data, 12, 425, 485, 518
 - non-linear relationship between serum 25OHD and vitamin D intake, 12, 99, 379–383, 384, 484
 - summary, 483–486
 - UL development, 404–405, 485
 - vitamin D as a prohormone, 75, 84, 481, 484

Uncertainty factor (UF), 29, 404–405, 420, 421, 422, 442

United States

- calcium intake assessment, 37, 463–465, 466
- compared with Canada, 474, 476–477
- national intake surveys, 10–11, 110, 457, 458–461, 521
- vitamin D deficiency, 13–14, 480, 486–488
- vitamin D intake assessment and serum 25OHD levels, 10–11, 110, 468–473

Units of measurement, 31–32, 78, 487

Upper Levels of Intake (ULs). *See* Tolerable Upper Intake Levels

Upper respiratory infections, 4, 5, 129, 169, 180–181

U.S. Department of Agriculture (USDA), 36, 38, 79, 458, 459, 462

U.S. Food and Drug Administration (FDA), 80, 167

V

Vaginosis, 192

Vanadium, 1115

Vascular endothelial growth factor (VEGF), 92

Vasodilation, 35, 43, 89

Vdr gene, 140, 168, 170, 172, 173, 178, 182, 184

Vdr-null mice, 91, 143, 148, 171, 173, 184, 251, 253, 259–260, 279

Vegetarian or vegan diet, 11, 63, 179, 496–498

Vision loss, 173

Vitamin A, 180, 1104, 1106, 1112

Vitamin B₆, 1105, 1107, 1113

Vitamin B₁₂, 1105, 1107, 1113

Vitamin C, 1104, 1106, 1112

Vitamin D. *See also* Calcitriol;

- 25-Hydroxyvitamin D; Serum 25-hydroxyvitamin D
- absorption, 83–84, 96
- adverse effects. *See* Adverse effects, vitamin D; Vitamin D, ULs
- AIs, 9, 363, 383, 385, 469
- anti-bacterial activity, 178, 181
- associations *vs.* causal or predictive relationships, 263–264, 480, 485, 517
- asthma, 169–170, 181
- bioaccumulation, 84, 87–88
- as biomarker of total intake, 12–13
- calcium regulation, 35, 40–41
- cancer
 - breast, 140–142, 435–436
 - colorectal, 143
 - overview, 135–139
 - pancreatic, 425, 436–437, 486
 - prostate, 146–147, 437
 - role in carcinogenesis, 91–92
- cardiovascular disease, 148, 149, 152
- cognitive function, 183–86, 188
- deficiency
 - autism, 182, 183
 - and bone metabolism, 35. *See also* Osteomalacia; Rickets
 - and cognitive function, 184, 185
 - colon cancer, 143
 - conclusions, 13–14, 293, 480, 486–488
 - defined by cut-point value, 480
 - indoor environments and institutionalized older persons, 241, 496
 - inflammatory bowel disease, 172
 - influenza and upper respiratory infections, 180
 - multiple sclerosis, 173
 - muscle weakness, 156–157
 - normal calcitriol levels, 97
 - pregnancy or lactation, 218, 251, 253–256, 259–260, 279–280
 - prostate cancer, 146–147
 - and serum 25OHD all-cause mortality, 432–435
 - and skin pigmentation, 481, 493–495
 - systemic lupus erythematosus, 176
 - type 1 diabetes, 171
- diabetes and, 153–155, 170, 171
- DRI development
 - analysis and outcomes, 380–383
 - conclusions, 366–370, 480
 - integration of evidence, 292–294, 370–379
 - interpretation of data in the literature, 292–294, 365–366, 370–379
 - in IOM 1997 report, 9, 16, 97, 346, 404, 425, 487
- DRI
 - adolescents, 385–387, 469, 1104
 - adults, 387–394, 469, 1104

- background of current report, 16, 346
- children, 385–387, 469, 1104
- in IOM 1997 report, 9, 16, 97, 346, 404, 425, 487
- lactation, 9, 363, 393, 394, 441, 446, 469, 1104
- pregnancy, 9, 363, 393, 394, 441, 446, 469, 1104
- EARs**
 - adolescents, 9, 363, 385, 387, 469, 1104
 - adults, 9, 363, 389, 392, 393, 394, 469, 1104
 - children, 9, 363, 385, 387, 469, 1104
 - lactation, 9, 363, 393, 394, 469, 1104
 - and outcome of physical performance, 167
 - pregnancy, 9, 363, 393, 394, 469, 1104
 - summary tables, 9, 363, 469, 1104
- elderly population and, 87, 219, 234–235, 496
- excretion, 86, 88
- food sources of, 79–83, 498
- formation, 6, 75–77, 84–85
- functions and physiological actions, 77–78, 89–94, 143, 153, 156, 176, 177, 180, 184, 251
- hormonal action and regulation, 6, 12, 515
- in human milk, 80, 94
- infants, 9, 363, 383, 385, 469, 504
- influenza and upper respiratory infections, 180
- intake. *See* Vitamin D intake
- intoxication, 6, 10, 88–89, 93, 405, 425, 426–430, 443, 518
- irritable bowel syndrome, 172
- during lactation, 9, 96, 257–260, 282–283, 393, 394
- lifetime, 86
- media coverage, 1, 16, 480
- metabolism, 35, 83–89, 92–93, 189
- multiple sclerosis, 173–174
- neuroprotective effects, 183–184
- non-linear relationship with serum 25OHD levels, 12, 99, 379–383, 384, 484
- during pregnancy, 191, 250–256, 279–281, 393–394
- as a prohormone, 75, 84, 481, 484
- RDAs**
 - adolescents, 9, 363, 385, 387, 469, 1106
 - adults, 9, 363, 389–390, 392, 393, 394, 469, 1106
 - children, 9, 363, 385, 387, 469, 1106
 - infants, 1106
 - lactation, 9, 363, 393, 394, 469, 1106
 - pregnancy, 9, 363, 393, 394, 469, 1106
 - summary tables, 9, 363, 469, 1106
- reference value development, 293–294, 480
- rheumatoid arthritis, 175
- serum 25OHD and. *See* Serum 25-hydroxyvitamin D, vitamin D and
- storage, 84, 87–88, 105–106, 156, 173, 370, 490, 492, 498, 518
- submariners, 83
- summary, 8–10, 363, 480
- sun exposure and. *See* Sun exposure supplementation. *See* Supplements, vitamin D
- synthesis in the skin, 6, 11, 81–83, 95, 100–105, 481, 493–495, 520
- synthetic analogues, 78, 81n.5
- systemic lupus erythematosus, 176–177
- threshold effect, 141, 515, 516
- ULs**
 - adolescents, 441, 469, 1112
 - adults, 441, 443–445, 469, 1112
 - children, 441, 445, 469, 1112
 - development, 10, 440–446, 488
 - infants, 440–442, 1112
 - lactation, 441, 446, 469, 1112
 - pregnancy, 441, 446, 469, 1112
 - summary tables, 9, 441, 469, 1112
 - uncertainties, 14, 486
 - units of measurement, 31–32
 - use of term, 78
- Vitamin D binding protein (DBP), 77, 84, 86, 88, 107, 251, 427
- Vitamin D External Quality Assurance Scheme (DEQAS), 109–110, 365
- Vitamin D intake
 - adverse effects. *See* Adverse effects, vitamin D; Vitamin D, ULs
 - assessment
 - approach, 462–463, 483
 - Canadian estimated, 474, 478

- Canadian surveys, 461–462, 499
 - estimates from national surveys, 10–11, 459–460
 - food sources only, 470, 474, 475, 476
 - summary, 477–478
 - U.S. estimated, 468–473
 - U.S. surveys, 458–461
 - assumption of adequacy for calcium DRI, 347
 - asthma, 169–170, 181
 - BMC/BMD and, 95, 175, 271, 274–275, 279–280, 386–387, 392–393
 - cardiovascular disease, 148, 149, 152
 - Crohn's disease, 172
 - diabetes, 155
 - excess, 88–89, 424–449, 481, 486, 517–518. *See also* Adverse effects, vitamin D; Indicators of adverse outcomes for excess intake
 - falls and physical performance, 157–165, 167, 438
 - fractures, 390, 438–439. *See also* Bone, fracture, vitamin D supplementation
 - indigenous Canadian populations, 498–499
 - intoxication, 6, 10, 88–89, 93, 405, 425, 426–430, 443, 518
 - during pregnancy, 169, 182, 279–281
 - rheumatoid arthritis, 175
 - serum 25OHD. *See* Serum 25-hydroxyvitamin D, vitamin D and; Sun exposure, relationship between serum 25OHD and vitamin D
 - from supplements. *See* Supplements, vitamin D
 - through the life stages, 8–10, 94–96
 - tuberculosis, 178, 179, 494
 - Vitamin D interactions
 - calcium, 5, 6, 35, 60, 136, 358, 360, 369, 388, 405, 484, 517
 - prescription drugs, 11, 87, 504, 505
 - Vitamin D receptor (VDR)
 - in the brain, 184
 - cancer, 91, 140, 146, 147
 - expressed in cells with rheumatoid lesions, 175
 - expressed in the duodenum, 38
 - expressed in the fetus, 252–253
 - expressed in the prostate, 146, 147
 - infants lacking, 254
 - lactation and, 91
 - muscle tissue, 157
 - regulation of expression by calcitriol, 38, 90, 91
 - rickets due to genetic absence of (VDDR II), 49, 94, 252, 254, 260, 276
 - use of term, 140n.1
 - Vitamin D response element (VDRE), 77, 140
 - Vitamin D₂
 - equivalence issues with vitamin D₃, 92–93, 97, 519
 - fortified foods, 80
 - metabolism, 86–87, 92–93
 - overview, 78
 - serum level as biomarker of total intake, 107, 108
 - supplementation, 81
 - toxicity, 93, 426
 - Vitamin D₃
 - deprivation, and autism, 182
 - equivalence issues with vitamin D₂, 92–93, 97, 519
 - fortified foods, 80
 - metabolism, 86–87, 92–93
 - overview, 78
 - serum level, not used to estimate synthesis in the skin, 104
 - serum level as biomarker of total intake, 107, 108
 - storage, 105
 - supplementation, 81, 107
 - synthesis in the skin. *See* Vitamin D, synthesis in the skin
 - toxicity, 93, 426
 - Vitamin E, 180, 1104, 1106, 1112
 - Vitamin K, 1106, 1112
 - Vitamins, 1106–1107, 1114–1115
 - Vomiting (emesis), 407, 409
- W**
- Water, 36, 411, 417, 1110
 - Weight, 140, 153, 192–193, 254, 406, 420, 425. *See also* Growth rate
 - Weight loss or dieting, 39, 106, 172, 518
 - West Indians, 245
 - What We Eat in America (WWEIA), 459, 473

White-matter hyperintensity volume, 185

Women. *See also* Females; Gender differences; Lactation; Menopausal status; Pregnancy

bone health

- fractures, 234–242, 257, 285–286, 357–358, 391, 392, 438, 439
- and serum 25OHD, 209–218, 226–234, 235
- vitamin D and calcium supplementation, 226, 234–242

calcium, 40, 58, 162, 226, 234–242, 356, 357–359, 360–361, 477, 480–481

cognitive function, 185

depression, 188

EARS, 356, 359, 360–361

falls, 157, 161, 162, 166, 438

glucose tolerance, 154

mean age of puberty, 24

nephrolithiasis, 411–412

RDAs, 356, 359

rheumatoid arthritis, 175

serum 25OHD level and cardiovascular risk, 437

systemic lupus erythematosus, 177

Women's Health Initiative (WHI), 138, 141, 185, 220, 234, 285, 298, 358, 393, 411–412, 413, 422

World Cancer Research Fund, 415

X

X-ray. *See* Dual-energy X-ray absorptiometry

Y

Young adults. *See* Adults, 19 through 30 years

Z

Zinc, 6, 37, 405, 417, 1105, 1109, 1115